γ-Aminobutyricacid (GABA) transporters 1 and 4 (mGAT1 and mGAT4) have been increasinglyrecognized as promising drug targets for neuropathic pain (NP) associatedwith imbalances in inhibitory neurotransmission. This evidence concerns the gene MGAT1 and neuropathic pain.